In animal studies, injecting GHK-Cu into thigh muscles improved healing at distant body locations, including the ears
To better understand biofilm development and persistence in chronic wounds, Figure 2 illustrates the stages of the biofilm life cycle, including adhesion, microcolony formation, maturation, and dispersion, as well as host immune responses such as neutrophil recruitment, M1/M2 macrophage polarization, and cytokine signaling (e.g., interleukin-1 beta [IL-1], tumor necrosis factor-alpha [TNF-], interleukin-6 [IL-6], interleukin-8 [IL-8], interleukin-12 [IL-12]), which collectively contribute to immune evasion and chronic infection [40-43]
Typical injectable GHK-Cu dose ranges Standard starting dose: 1 mg per day subcutaneous Conservative / beginner dose: 0.5 mg per day Intensive / wound-healing dose: 23 mg per day Upper research range: 4 mg per day (rarely exceeded) Frequency: once daily, or split into morning + evening microdoses for steadier levels Route: subcutaneous (SC) injection - typically abdomen , thigh or flank
Despite its therapeutic promise, more studies are needed to confirm its efficacy and safety for clinical use
